A Phase I Study of a Recombinant Chimeric Protein Composed of Circularly Permuted IL-4 and a Mutated Form of the Pseudomonas Exotoxin Termed IL-4(38-37)-PE38KDEL (IL-4 Toxin) for the Treatment of Recurrent Malignant Astrocytoma

Trial Profile

A Phase I Study of a Recombinant Chimeric Protein Composed of Circularly Permuted IL-4 and a Mutated Form of the Pseudomonas Exotoxin Termed IL-4(38-37)-PE38KDEL (IL-4 Toxin) for the Treatment of Recurrent Malignant Astrocytoma

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs MDNA 55 (Primary)
  • Indications Astrocytoma; Glioblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Nov 2017 According to a Medicenna Therapeutics media release, results were presented at Cancer Prevention and Research Conference held from November 13-14, 2017 in Austin.
    • 14 Nov 2017 Results published in the Medicenna Therapeutics media release.
    • 24 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top